InvestorsHub Logo
Followers 831
Posts 120032
Boards Moderated 17
Alias Born 09/05/2002

Re: dewophile post# 2959

Monday, 05/13/2024 3:20:22 PM

Monday, May 13, 2024 3:20:22 PM

Post# of 3019
More on Shionogi’s COVID trial:

https://www.fiercepharma.com/pharma/shionogis-homegrown-antiviral-comes-short-global-covid-trial

Notably, the article cites Shionogi’s CEO saying that Xocova could generate $2B of annual sales if approved in the US. It’s unclear how much of this hypothetical sales figure comes from COVID patients who would otherwise have taken Paxlovid vs COVID patients who would otherwise have taken no drug.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ENTA News